Shopping Cart
- Remove All
- Your shopping cart is currently empty
LSD1-IN-25 (Compound 9j) is a potent, selective, and orally active LSD1 inhibitor with an IC50 of 46 nM (Ki = 30.3 nM) that induces apoptosis in cancer cells [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | LSD1-IN-25 (Compound 9j) is a potent, selective, and orally active LSD1 inhibitor with an IC50 of 46 nM (Ki = 30.3 nM) that induces apoptosis in cancer cells [1]. |
Targets&IC50 | LSD1:46 nM, LSD1:30.3 nM (Ki) |
In vitro | LSD1-IN-25 (Compound 9j; 0-20 μM; 72 h) inhibits solid tumor cell proliferation [1] and, at 1-4 μM concentrations over 24 hours, increases H3K4me2 levels while inhibiting epithelial-mesenchymal transition (EMT) in H1650 cells [1]. Furthermore, LSD1-IN-25 (1-4 μM; 24 h) induces apoptosis and S-phase arrest in H1650 cells [1]. |
In vivo | LSD1-IN-25 (Compound 9j; 10 and 20 mg/kg; oral gavage; daily for 21 days) demonstrated antitumor activity in an H1650 cell xenograft mouse model [1]. |
Molecular Weight | 617.16 |
Formula | C32H33ClN6O3S |
Cas No. | 2911585-60-7 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.